Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor (GIST): ACOSOG Z9000 (Alliance) intergroup phase 2 trial

OBJECTIVE: To conduct the first adjuvant trial of imatinib mesylate for treatment of gastrointestinal stromal tumor (GIST). SUMMARY BACKGROUND DATA: GIST is the most common sarcoma. While surgical resection has been the mainstay of therapy for localized, primary GIST, postoperative tumor recurrence...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: DeMatteo, Ronald P., Ballman, Karla V., Antonescu, Cristina R., Corless, Christopher, Kolesnikova, Violetta, von Mehren, Margaret, McCarter, Martin D., Norton, Jeffrey, Maki, Robert G., Pisters, Peter W.T., Demetri, George D., Brennan, Murray F., Owzar, Kouros
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4041735/
https://ncbi.nlm.nih.gov/pubmed/23860199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/SLA.0b013e3182a15eb7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados